Literature DB >> 21304215

Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients.

Yoshiaki Kawagoe1, Yoshiyuki Hattori, Ayuko Nakano, Chie Aoki, Seiichi Tanaka, Satoshi Ohta, Toshie Iijima, Atsuko Tomizawa, Teruo Jojima, Hiroyuki Kase, Kikuo Kasai.   

Abstract

It is well established that statins improve the prognosis of patients with coronary artery disease. However, it is still unclear whether the protective effects of statins relate to lipid lowering alone or whether other pleiotropic effects may contribute. Thus, we compared the endothelial function among two groups of diabetic patients treated with fluvastatin 60 mg (F60) or fluvastatin 20 mg combined with ezetimibe 10 mg (F20/E10). The endothelial function was evaluated by measuring flow-mediated vasodilatation (FMD) at baseline and follow-up at 10 weeks. Similar improvements in FMD were observed in the two groups. The reduction in low-density lipoprotein cholesterol (LDL-C) was less pronounced in the F60 group, compared with the F20/E10 group. A significant reduction in remnant-like lipoprotein particles cholesterol (RLP-C) was observed in the F20/E10 group, but not in the F60 group. A correlation between the observed reduction in LDL-C or RLP-C and the improvement in FMD was observed in F20/E10 group. These results suggest that high-dose fluvastatin might have pleiotropic effects of potential clinical benefit, and that the combination of ezetimibe with a reduced dose of fluvastatin may also significantly improve endothelial function with reduction of LDL-C and RLP-C.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304215     DOI: 10.1507/endocrj.k10e-289

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

Review 1.  Pleiotropic Effects of Statins on the Cardiovascular System.

Authors:  Adam Oesterle; Ulrich Laufs; James K Liao
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

Review 2.  The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Seyyed Mostafa Arabi; Mahla Chambari; Mahsa Malek-Ahmadi; Leila Sadat Bahrami; Vahid Hadi; Manfredi Rizzo; Amirhossein Sahebkar
Journal:  Inflammopharmacology       Date:  2022-08-21       Impact factor: 5.093

Review 3.  Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Huijin Wu; Hua Shang; Jing Wu
Journal:  Endocrine       Date:  2018-02-03       Impact factor: 3.633

4.  Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks.

Authors:  Yu-Cheng Kao; Tien-Hsing Chen; Chi-Hung Liu; Jawl-Shan Hwang; Ching-Chung Hsiao; Yu-Sheng Lin; Chun-Tai Mao; Ming-Jui Hung; Yan-Rong Li
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

5.  Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.

Authors:  Andrei C Sposito; Ikaro Breder; Joaquim Barreto; Jessica Breder; Isabella Bonilha; Marcus Lima; Alessandra Oliveira; Vaneza Wolf; Beatriz Luchiari; Helison R do Carmo; Daniel Munhoz; Daniela Oliveira; Otavio R Coelho-Filho; Otavio R Coelho; Jose Roberto Matos-Souza; Filipe A Moura; Luiz Sergio F de Carvalho; Wilson Nadruz; Thiago Quinaglia; Sheila T Kimura-Medorima
Journal:  Cardiovasc Diabetol       Date:  2022-08-06       Impact factor: 8.949

6.  RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale.

Authors:  Takeshi Inazawa; Kentaro Sakamoto; Takahide Kohro; Raisuke Iijima; Toru Kitazawa; Tsutomu Hirano; Mitsunobu Kawamura; Motoki Tagami; Akira Tanaka; Yasumichi Mori; Tsutomu Yamazaki; Teruo Shiba
Journal:  Lipids Health Dis       Date:  2013-10-05       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.